Abzena PLC Abzena secures ADC manufacturing services contract (8914Y)
December 11 2017 - 2:00AM
UK Regulatory
TIDMABZA
RNS Number : 8914Y
Abzena PLC
11 December 2017
Abzena plc
Abzena secures contract for integrated ADC manufacturing
services to US biotech company
Cambridge, UK, 11 December 2017 - Abzena plc (AIM: ABZA,
'Abzena' or the 'Group'), a life sciences group providing services
and technologies enabling the development and manufacture of
biopharmaceutical products, has entered into a Master Services
Agreement with a US biotech company to provide process development
and manufacturing services to progress a novel antibody-drug
conjugate ("ADC") towards clinical trials.
The value of the entire process development and GMP
manufacturing services exceeds $5 million, with the majority of the
services to be provided within the next 12 months. The services
will be carried out principally by Abzena's chemistry and
biomanufacturing groups in Bristol, PA and San Diego, CA.
Abzena has worked with the US-based company for a number of
years, with the relationship built around Abzena's chemistry
services. Following the initial chemistry development, Abzena
subsequently developed a cell line that will now be used to produce
the antibody at its GMP manufacturing facility. Abzena will also
conduct GMP production of the ADC payload reagent and the
conjugation process to create the ADC for initial clinical
study.
In entering into the Master Services Agreement with Abzena, the
US biotech company has selected Abzena as its preferred chemistry
services and manufacturing provider for its ADC program.
John Burt, CEO of Abzena, said: "Since the expansion of Abzena's
service offering into the US with two acquisitions in 2015, we have
seen a number of customer relationships expand. They are using more
of our services across the Group's biology, chemistry and
manufacturing capabilities.
"This latest deal further consolidates our existing relationship
with our customer. Drawing on Abzena's integrated service offering,
this ADC can progress through the preclinical and clinical trial
process, with the ultimate goal of developing a new potential
treatment."
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer Julian Smith, Chief
Financial Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black +44 20 7260
/ Paul Gillam 1000
N+1 Singer (Joint Broker) +44 20 7496
Aubrey Powell / Liz Yong 3000
Instinctif Partners +44 20 7457
Melanie Toyne Sewell / Alex 2020
Shaw / Deborah Bell abzena@instinctif.com
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity
assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTTMBITMBBBBIR
(END) Dow Jones Newswires
December 11, 2017 02:00 ET (07:00 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2023 to Apr 2024